SUTRO BIOPHARMA, INC. (STRO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US8693672011
SUTRO BIOPHARMA, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 102.48 m USD |
| Operating income | -158.37 m USD |
| EBIT | -191.18 m USD |
| Net income | -191.09 m USD |
| Diluted EPS – continuing operations | -22.49 USD |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About SUTRO BIOPHARMA, INC.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
More stocks
- EGAIN Corp (EGAN)
- Gevelot (ALGEV.PA)
- Iron Force Industrial Co Ltd (2228.TW)
- Neostellar Capital Corp. (NSLR)
- Saniona AB (SANION.ST)
- United Fiber Optic Communication Inc. (4903.TWO)
- Genovis AB (publ.) (GENO.ST)
- Huckleberry.ai, Inc. (HUCK)
- Interlife General Insurance S.A. (INLIF.AT)
- LEE ENTERPRISES, Inc (LEE)
- Kolon Globalco (003070.KS)
- Sammok S-Form Co.Ltd (018310.KQ)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.